Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$3.155
−$1.725 · -35.35%
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
Regular session
$3.155
−$1.725 · -35.35%
Regular session · ET · Market data may be delayed.
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
Day range
Current $3.155
52-week range
Current $3.155
Regular session · ET · Market data may be delayed.
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.
Day range
Current $3.155
52-week range
Current $3.155
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
